Vedanta Partners Adjusts Stake in Reviva Pharmaceuticals

TL;DR

Vedanta Partners filed an amendment to their 13D for Reviva Pharma, watch this space.

AI Summary

Vedanta Partners, LLC, through its filing on May 31, 2024, has amended its Schedule 13D/A regarding Reviva Pharmaceuticals Holdings, Inc. The filing indicates a change in beneficial ownership, with Vedanta Partners, LLC now holding a significant stake. The specific percentage and number of shares are detailed within the full filing.

Why It Matters

This filing signals a potential shift in control or influence over Reviva Pharmaceuticals, which could impact its strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate activist investor activity or significant shifts in a company's shareholder base, introducing potential volatility.

Key Players & Entities

• Vedanta Partners, LLC (company) — Filing entity
• Reviva Pharmaceuticals Holdings, Inc. (company) — Subject company
• Parag Saxena (person) — Authorized contact for Vedanta Partners, LLC
• Tenzing Acquisition Corp. (company) — Former company name for Reviva Pharmaceuticals Holdings, Inc.

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
• $0.0001 — relates to the shares of common stock, $0.0001 par value per share (“ Common Sto
• $6.04 — rlying options, at an exercise price of $6.04 per share, granted by the Issuer to Mr.

Filing Documents

• formsc13da.htm (SC 13D/A) — 161KB
• 0001493152-24-022270.txt ( ) — 162KB

for additional information

Item 5 for additional information. CUSIP No. 76152G 100 1. Names of Reporting Persons. Vedanta Associates, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions) WC, AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 3,408,401 9. Sole Dispositive Power 0 10. Shared Dispositive Power 3,408,401 11. Aggregate Amount Beneficially Owned by Each Reporting Person 3,408,401 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 10.4%* 14. Type of Reporting Person (See Instructions) PN *See Item 5 for additional information. CUSIP No. 76152G 100 1. Names of Reporting Persons. Beta Operators Fund, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 2,138,130 9. Sole Dispositive Power 0 10. Shared Dispositive Power 2,138,130 11. Aggregate Amount Beneficially Owned by Each Reporting Person 2,138,130 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 6 .8%* 14. Type of Reporting Person (See Instructions) PN *See

for additional information

Item 5 for additional information. CUSIP No. 76152G 100 1. Names of Reporting Persons. Vedanta Partners, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 5 ,367,069 9. Sole Dispositive Power 0 10. Shared Dispositive Power 5 ,367,069 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5 ,367,069 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 15.9%* 14. Type of Reporting Person (See Instructions) OO *See

for additional information

Item 5 for additional information. CUSIP No. 76152G 100 1. Names of Reporting Persons. Parag Saxena 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions) WC, AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization India Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 884,537 8. Shared Voting Power 5,367,069 9. Sole Dispositive Power 884,537 10. Shared Dispositive Power 5,367,069 11. Aggregate Amount Beneficially Owned by Each Reporting Person 6,251,606 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 18.5%* 14. Type of Reporting Person (See Instructions) IN *See

for additional information

Item 5 for additional information. Explanatory Note This Amendment No. 7 to Schedule 13D (this “ Amendment No. 7 ”) filed on behalf of Parag Saxena, Vedanta Partners, LLC, Beta Operations Fund, L.P., Vedanta Associates, L.P., and Vedanta Associates-R, L.P. (collectively, the “ Reporting Persons ”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “ SEC ”) on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, by Amendment No. 4 on June 3, 2021, by Amendment No. 5 on September 12, 2022, and by Amendment No. 6 on November 30, 2023 (as amended, the “ Schedule 13D ”). Except as specifically provided herein, this Amendment No. 7 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Item 1. Security and Issuer Item 1 of the Schedule 13D is amended and restated as follows: This Amendment No. 7 relates to the shares of common stock, $0.0001 par value per share (“ Common Stock ”), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “ Issuer ”), which has its principal executive offices at 10080 N. Wolfe Road, Suite SW3-200, Cupertino, CA 95014. Item 5. Interest in Securities of the Issuer Item 5 of the Schedule 13D is amended and supplemented as follows: (a) The information set forth in rows 11 and 13 of the cover pages to this Amendment No. 7 are incorporated by reference into this Item 5. The percentages set forth in row 13 of each cover page is based on 29,817,294 outstanding shares of Common Stock as of May 29, 2024, as reported directly by the Issuer to the Reporting Persons. (b) The information set forth in rows 7 through 10 of the cover pages to this Amendment No. 7 are incorporated by r

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: May 31, 2024 VEDANTA ASSOCIATES-R, L.P. By: Vedanta Partners, LLC, the general partner of Vedanta Associates-R, L.P. By: /s/ Parag Saxena Name: Parag Saxena Title: CEO VEDANTA ASSOCIATES, L.P. By: Vedanta Partners, LLC, the general partner of Vedanta Associates, L.P. By: /s/ Parag Saxena Name: Parag Saxena Title: CEO BETA OPERATORS FUND, L.P. By: Vedanta Associates, L.P., the general partner of Beta Operators Fund, L.P. By: Vedanta Partners, LLC, the general partner of Vedanta Associates, L.P. By: /s/ Parag Saxena Name: Parag Saxena Title: CEO VEDANTA PARTNERS, LLC By: /s/ Parag Saxena Name: Parag Saxena Title: CEO /s/ Parag Saxena PARAG SAXENA Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).